• Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $3.98​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of $4.20. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.03 per share. Wall Street expected results to range from $3.41 to $4.85 per share.

• Revenue rose 15.7% to $2.91 billion from a year ago; analysts expected $2.78 billion.

• Vertex Pharmaceuticals Inc's reported EPS for the quarter was $3.50​.

• The company reported quarterly net income of $913 million.

• Vertex Pharmaceuticals Inc shares had risen by 16.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.8% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 11 "hold" and 2 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Vertex Pharmaceuticals Inc is $520.00

This summary was machine generated from LSEG data February 10 at 10:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)